KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Non-Current Deffered Revenue (2016 - 2023)

NovoCure (NVCR) has disclosed Non-Current Deffered Revenue for 9 consecutive years, with $807000.0 as the latest value for Q2 2023.

  • Quarterly Non-Current Deffered Revenue fell 82.23% to $807000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $807000.0 through Jun 2023, down 82.23% year-over-year, with the annual reading at $2.9 million for FY2022, 55.57% down from the prior year.
  • Non-Current Deffered Revenue hit $807000.0 in Q2 2023 for NovoCure, down from $1.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $12.1 million in Q4 2020 to a low of $807000.0 in Q2 2023.
  • Historically, Non-Current Deffered Revenue has averaged $7.0 million across 5 years, with a median of $7.9 million in 2019.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 55.49% in 2020 and later crashed 82.23% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $7.8 million in 2019, then skyrocketed by 55.49% to $12.1 million in 2020, then crashed by 46.64% to $6.5 million in 2021, then tumbled by 55.57% to $2.9 million in 2022, then crashed by 71.96% to $807000.0 in 2023.
  • Business Quant data shows Non-Current Deffered Revenue for NVCR at $807000.0 in Q2 2023, $1.8 million in Q1 2023, and $2.9 million in Q4 2022.